TITLE

ZOGENIX GETS 2011 DRUG DELIVERY AWARD FOR SUMAVEL DOSEPRO

PUB. DATE
March 2011
SOURCE
Worldwide Biotech;Mar2011, Vol. 23 Issue 3, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Zogenix Inc. has been awarded with the 2011 Drug Delivery Partnerships (DDP) Innovation Award in the Industry Achievement Category for its SUMAVEL Dose Pro (sumatriptan injection) needle-free delivery system.
ACCESSION #
58691939

 

Related Articles

  • New formulation.  // Formulary;Sep2009, Vol. 44 Issue 9, p263 

    The article evaluates the Sumavel DosePro medicine from Zogenix Inc.

  • Former Diet Drug May Treat Seizures. Meiling, Brittany // San Diego Business Journal;6/8/2015, Vol. 36 Issue 23, p3 

    The article focuses on a finding by San Diego drugmaker Zogenix Inc. that a rare disease that causes severe seizures in young children could be treated by a drug once used to fight obesity before it was taken off the market.

  • Controversy surrounds FDA approval of Zohydro. Young, Cara Aldridge // Pharmacy Today;Dec2013, Vol. 19 Issue 12, p48 

    Information on the hydrocodone bitartrate extended-capsule Zohydro ER from Zogenix Inc. is presented.

  • Aradigm wins $4 million milestone payment from Zogenix.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p18 

    No abstract available.

  • Company Invests $105.3M to Develop, Market Promising Drug. Quigley, Kelly // San Diego Business Journal;7/18/2011, Vol. 32 Issue 29, p11 

    The article reports on the move of the San Diego, California-based pharmaceutical company Zogenix Inc. to spend as much 105.3 million U.S. dollars to develop and market the schizophrenia drug Relday.

  • Zohydro faces a possible competitor. Weinstein, Deborah // Medical Marketing & Media;Apr2014, Vol. 49 Issue 4, p11 

    The article reports on the approval issues facing hydrocodone medication Zohydro, made by Zogenix Inc.

  • Did "pay-to-play" confab help Zohydro approval? Dickinson, James G. // Medical Marketing & Media;Apr2014, Vol. 49 Issue 4, p28 

    The article reports on the influence of the meeting between pharmaceutical industry executives and the U.S. Food and Drug Administration (FDA) officials on the agency's approval of Zogenix Inc.'s Zohydro prescription painkiller.

  • Zogenix initiates Phase III pain trial.  // PharmaWatch: CNS;May2010, Vol. 9 Issue 5, p11 

    The article reports on the Phase III clinical trial ZX002 designed for patients with lower back pain initiated by Zogenix Inc.

  • Financings Roundup.  // BioWorld Today;7/25/2012, Vol. 23 Issue 143, p7 

    The article reports on the launch of a public offering of 32.5 million units of common stock and warrant by Zogenix Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics